Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

211
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
211

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo efficacy of current stimuli computed by optimal tracking of neuron membrane voltage.

PloS one·2026
Same author

An alpha7 nicotinic acetylcholine receptor agonist induces retinal neurogenesis and restores electrophysiological function following blast-induced ocular trauma in adult mice.

Frontiers in neuroscience·2025
Same author

Does the output form of inhibition of return operate at or after the bottleneck?

Acta psychologica·2025
Same author

Assessing Posner's theory of alerting: A meta-analysis of speed-accuracy effects.

Attention, perception & psychophysics·2025
Same author

Quantification of Proliferating and Mitotically Active Retinal Cells in Mice by Flow Cytometry.

Bio-protocol·2024
Same author

Target identification and validation of the alpha7 nicotinic acetylcholine receptor as a potential therapeutic target in retinal disease.

Frontiers in ophthalmology·2024

Related Experiment Video

Updated: Mar 26, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Neuroprotective Strategies in Glaucoma.

Cynthia A Gossman, John Christie, Mark K Webster

  • 1Western Michigan University, Department of Biological Sciences, Kalamazoo, MI 49008. Cindy.linn@wmich.edu.

Current Pharmaceutical Design
|January 29, 2016
PubMed
Summary
This summary is machine-generated.

Neuroprotective strategies aim to prevent vision loss in glaucoma by protecting retinal ganglion cells (RGCs). Future glaucoma treatments may combine these approaches with intraocular pressure (IOP) reduction.

More Related Videos

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K
A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Cell Biology

Background:

  • Glaucoma is a neuropathic disease causing progressive retinal ganglion cell (RGC) degeneration and irreversible vision loss.
  • Current glaucoma treatments focus on reducing intraocular pressure (IOP), but are insufficient to halt disease progression.
  • Neuroprotective strategies are crucial for preventing retinal neuron loss and disease advancement.

Purpose of the Study:

  • To review and discuss neuroprotective strategies for glaucoma, focusing on the retina and ganglion cell layer.
  • To present recent and past neuroprotective therapies aimed at preventing RGCs, optic nerve axon, and vision loss in glaucoma.

Main Methods:

  • Literature review of neuroprotective strategies in glaucoma.
  • Analysis of pharmacological, stem cell, gene therapy, and viral research approaches.

Main Results:

  • Pharmacological treatments target receptors, signaling pathways, and neurotrophic factors to induce retinal neuroprotection.
  • Approaches address mechanisms of cellular loss, including excitotoxicity, oxidative stress, and apoptosis.
  • Stem cell therapy, gene therapy, and viral research show promise in neuroprotection against RGC loss in glaucoma.

Conclusions:

  • Future glaucoma treatment likely involves a combination of neuroprotective strategies.
  • These combined treatments aim to prevent the underlying pathophysiology of glaucoma.
  • This integrated approach holds promise for halting disease progression and preserving vision.